NASDAQ · Medical - Diagnostics & Research

Natera, Inc. (NTRA) Stock

$400.96 +2.60% NASDAQ: NTRA Healthcare

Valuation

MetricValue
Price$400.96
Market Cap$57.42B
P/E Ratio-299.33
P/B Ratio32.02
P/S Ratio21.54
EPS (TTM)$-0.68
52-Week High$427.47
52-Week Low$160.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-11.73%
ROA-7.24%
ROCE-13.77%
Gross Margin-13.44%
Operating Margin-13.44%
Net Margin-7.11%
Debt/Equity0.13
Current Ratio3.39

Annual Financials (USD)

Metric20212022202320242025
Revenue$625.0M$820.0M$1.1B$1.7B$2.3B
Operating Profit$-468.0M$-541.0M$-446.0M$-222.0M$-310.0M
Net Profit$-472.0M$-548.0M$-435.0M$-190.0M$-208.0M
EPS$-5.21$-5.57$-3.78$-1.53$-1.52
Op Margin-74.8%-66.0%-41.2%-13.1%-13.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.2B$1.4B$1.4B$1.7B$2.5B
Total Liabilities$583.0M$689.0M$676.0M$465.0M$796.0M
Cash$84.0M$466.0M$642.0M$946.0M$1.1B
Borrowings$397.0M$446.0M$442.0M$187.0M$214.0M

Latest News

Cathie Wood Loads Up on SpaceX, Meta, Eli Lilly and Circle Group GuruFocus.com · Jul 13, 2026 Did EU Class C Status for Signatera Reshape Natera’s (NTRA) Long-Term Diagnostics Strategy? Simply Wall St. · Jul 11, 2026 Natera (NTRA) Secures EU Certification, Is The Upside Already Priced In? Simply Wall St. · Jul 10, 2026 Natera (NTRA) Signatera Data Shows Who Benefits From Chemotherapy After CRC Surgery Simply Wall St. · Jul 10, 2026 Cathie Wood Dumps AMD, Doubles Down on Meta Stock GuruFocus.com · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-335.0M$-432.0M$-247.0M$136.0M$215.0M
Investing Cash Flow$-246.0M$283.0M$129.0M$71.0M$-238.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$36.0M$381.0M$176.0M$303.0M$131.0M
Free Cash Flow$-376.0M$-479.0M$-286.0M$69.0M$109.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-18.44
EV / EBITDA-320.69
FCF Yield0.12%
Quick Ratio2.85
Interest Coverage-29.04
Return 1Y154.34%
Return 3Y877.36%
Return 5Y283.46%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BLLNBillionToOne, Inc. $97.95 +2.66% 154.24 $4.51B 0.00%
FLGTFulgent Genetics, Inc. $21.46 +3.07% -7.62 $609.48M 0.00%
MYGNMyriad Genetics, Inc. $4.20 -1.87% -3.80 $396.68M 0.00%
PSNLPersonalis, Inc. $16.08 +0.09% -14.94 $1.72B 0.00%
SERASera Prognostics, Inc. $2.02 -2.42% -3.12 $77.15M 0.00%

About Natera, Inc.

Natera, Inc. is led by CEO Steven Leonard Chapman, employs 4,424 people, headquartered in Austin, US, publicly traded since 2015.

Natera, Inc. (NTRA) stock trades at $400.96 with a market capitalization of $57.42B. The stock is valued at a price-to-earnings (P/E) ratio of -299.33, price-to-book of 32.02, price-to-sales of 21.54. Over the past 52 weeks the stock has ranged between $160.59 and $427.47, and currently trades 6.2% below its 52-week high.

On profitability, Natera, Inc. generates a return on equity (ROE) of -11.73%, return on capital employed of -13.77%, an operating margin of -13.44%, a net profit margin of -7.11%.

In its most recent fiscal year, Natera, Inc. reported annual revenue of $2.3B, net profit of $-208.0M, revenue has compounded at 42.6% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.13 — a conservative balance sheet with little leverage risk, a current ratio of 3.39, total assets of $2.5B, $1.1B in cash and equivalents.

NTRA has a beta of 1.53 (more volatile than the overall market).

Related Healthcare Stocks

LLY Eli Lilly and Company $1177.49 +0.67% JNJ Johnson & Johnson $260.66 +1.63% ABBV AbbVie Inc. $277.31 +1.80% MRK Merck & Company, Inc. Common Stock (new) $145.87 +2.45% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.88 +1.60% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $659.76 +1.19% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $151.18 +2.77% ABT Abbott Laboratories $99.45 +0.97% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides